IGFR-Like Receptor Antibodies for Early Diabetes Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments lack reliable biomarkers for early diagnosis and effective interventions to prevent or reverse insulin resistance and β-cell loss, and existing therapies have safety concerns and limited efficacy.
Innovation Solution
Development of IGFR-like receptor antagonists and agonists, specifically targeting epitopes of the IGFR-like receptor, to modulate insulin signaling and pancreatic β-cell function, offering diagnostic and therapeutic options for diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diabetes treatments are used, then diabetes management is maintained, but reliable biomarkers for early diagnosis and effective interventions to prevent or reverse insulin resistance are lacking
Solution Approach 1:
The patent segments the diabetes detection and treatment approach by identifying specific epitopes (SEQ ID NO: 2-6) of the IGFR-like receptor as distinct biomarker targets. This segmentation enables development of targeted antibodies for early diagnosis, separating early detection from general diabetes management.
Solution Approach 2:
The patent enables preliminary action by providing biomarkers that allow early diagnosis of diabetes before significant β-cell loss occurs. The identified epitopes serve as early warning signals, allowing interventions to be initiated before the disease progresses to irreversible stages.
2Reliability
If existing diabetes therapies are administered, then some diabetes management is achieved, but safety concerns and limited efficacy prevent reversal of insulin resistance and β-cell loss
Solution Approach 1:
The patent introduces antibodies targeting specific epitopes of the IGFR-like receptor as intermediary agents. These antibodies selectively modulate insulin signaling through the IGFR-like receptor without affecting other insulin pathways, providing a safer and more specific therapeutic mechanism compared to existing broad-acting diabetes medications.
Solution Approach 2:
The patent applies local quality by targeting specific epitopes (SEQ ID NO: 2-6) of the IGFR-like receptor rather than affecting all insulin receptors uniformly. This localized targeting allows selective modulation of insulin signaling pathways, achieving therapeutic effects with reduced off-target side effects.
3Adaptability or versatility
If IGFR-like receptor antagonists and agonists are developed, then novel therapeutic options for diabetes are provided, but the complexity of targeting specific epitopes increases
Solution Approach 1:
The patent achieves universality by identifying five different epitopes (SEQ ID NO: 2-6) on the IGFR-like receptor that can all be targeted by antibody-based therapies. This multi-epitope approach provides multiple avenues for drug development, allowing researchers to select from various target sites depending on the desired therapeutic profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IGFR-like receptor provides a novel target for treating diabetes by reversing insulin resistance and preventing β-cell de-differentiation, enabling early diagnosis and potential cure.
Implementation Method 1
anti-IGFR-like receptor antibodies specifically binding to an epitope of the IGFR-like receptor
Data Source
AI summary
The present invention provides a novel IGFR-like receptor and antagonists and agonists for targeting said receptor. Said antagonists and agonists are envisaged for use as a medicament, and in particular for treatment of diabetes.